Biond Biologics
Biotechnology company developing first-in-class biologic therapeutics focused on immuno-oncology and immune-mediated diseases. Maintains a discovery and preclinical portfolio and multiple clinical-stage antibody programs (Phase 1–2). Engages in translational research, biomarker identification, and strategic partnerships including licensing agreements.
Industries
Nr. of Employees
small (1-50)
Patents
Products
BND-22 (ILT2-blocking antibody)
First-in-class antibody targeting the ILT2 receptor; advanced in clinical development (Phase 1–2) for multiple solid tumor indications and evaluated in combination regimens.
BND-67 (CD28 shedding inhibitor)
Antibody-based therapeutic designed to prevent pathological CD28 shedding, aiming to enhance effector T-cell activity and selectively inhibit regulatory T cells; evaluated in Phase 1 studies.
BND-35 (ILT3-targeting antibody)
Antibody targeting the ILT3 receptor developed for tumors with suppressive tumor microenvironments; reported to have an acceptable safety profile in dose-escalation studies.
BND-67
BND-67 is a first-in-class, VHH-based antibody designed to inhibit pathological CD28 shedding, enhancing effector T-cell activation and expansion while reducing the suppressive activity of regulatory T cells.
BND-22
BND-22 (SAR444881) is a first-in-class humanized IgG4 antagonist antibody targeting ILT2 (LILRB1), an inhibitory receptor expressed on both innate and adaptive immune cells.
BND-35
BND-35 is an innovative antibody targeting the Ig-like transcript 3 (ILT3) receptor, in development for the treatment of solid tumors known to have a suppressive tumor microenvironment (TME).
BND-22 (ILT2-blocking antibody)
First-in-class antibody targeting the ILT2 receptor; advanced in clinical development (Phase 1–2) for multiple solid tumor indications and evaluated in combination regimens.
BND-67 (CD28 shedding inhibitor)
Antibody-based therapeutic designed to prevent pathological CD28 shedding, aiming to enhance effector T-cell activity and selectively inhibit regulatory T cells; evaluated in Phase 1 studies.
BND-35 (ILT3-targeting antibody)
Antibody targeting the ILT3 receptor developed for tumors with suppressive tumor microenvironments; reported to have an acceptable safety profile in dose-escalation studies.
BND-67
BND-67 is a first-in-class, VHH-based antibody designed to inhibit pathological CD28 shedding, enhancing effector T-cell activation and expansion while reducing the suppressive activity of regulatory T cells.
BND-22
BND-22 (SAR444881) is a first-in-class humanized IgG4 antagonist antibody targeting ILT2 (LILRB1), an inhibitory receptor expressed on both innate and adaptive immune cells.
BND-35
BND-35 is an innovative antibody targeting the Ig-like transcript 3 (ILT3) receptor, in development for the treatment of solid tumors known to have a suppressive tumor microenvironment (TME).
Expertise Areas
- Immuno-oncology drug discovery
- Monoclonal antibody development
- Preclinical translational research
- Early-phase clinical development (Phase I/II)
Key Technologies
- Monoclonal antibodies
- Immune checkpoint modulation
- Preclinical in vitro/ex vivo/in vivo models
- Biomarker identification
News & Updates
Participation and presentations at conferences including BIO International Convention, ASCO Annual Meeting, AACR, BIO Europe Spring, and J.P. Morgan Healthcare Conference.
Publication reporting that a humanized ILT2-blocking antibody promoted antitumor immunity and tumor regression in preclinical models.
Executed a global licensing agreement for the ILT2-targeting program with a major pharmaceutical company.
Announced dosing of the first patient in a Phase 1 clinical trial of the ILT2-blocking antibody.
Reported first patients dosed with combination regimens including the ILT2-targeting antibody in a Phase 1 trial.
Closed a $15 million Series C financing round to support company programs.
Participation and presentations at conferences including BIO International Convention, ASCO Annual Meeting, AACR, BIO Europe Spring, and J.P. Morgan Healthcare Conference.
Publication reporting that a humanized ILT2-blocking antibody promoted antitumor immunity and tumor regression in preclinical models.
Executed a global licensing agreement for the ILT2-targeting program with a major pharmaceutical company.
Announced dosing of the first patient in a Phase 1 clinical trial of the ILT2-blocking antibody.
Reported first patients dosed with combination regimens including the ILT2-targeting antibody in a Phase 1 trial.
Closed a $15 million Series C financing round to support company programs.